Tc 99m tilmanocept

DRUG5 trials

Sponsors

Navidea Biopharmaceuticals, Memorial Health University Medical Center, Duke University

Conditions

Breast CancerCardiac SarcoidosisKaposi's SarcomaRheumatoid ArthritisSentinel Lymph Node Biopsy

Phase 2

Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

CompletedNCT02201420

Navidea BiopharmaceuticalsKaposi's Sarcoma

Start: 2014-09-30End: 2015-10-31Updated: 2016-09-27

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

CompletedNCT03938636

Navidea BiopharmaceuticalsRheumatoid Arthritis

Start: 2019-04-08End: 2021-06-30Updated: 2023-08-24

Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

TerminatedNCT04078191

Navidea BiopharmaceuticalsRheumatoid Arthritis

Start: 2021-09-14End: 2024-07-09Updated: 2025-01-08

Repurposing Tilmanocept for Cardiac Sarcoidosis

RecruitingNCT07159074

Duke UniversityCardiac Sarcoidosis

Start: 2025-09-17End: 2026-12-31Target: 15Updated: 2026-03-27

Phase 4

Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy

Memorial Health University Medical CenterBreast Cancer, Sentinel Lymph Node Biopsy

Start: 2017-06-22End: 2019-08-22Target: 86Updated: 2018-08-24